IMR Press / FBL / Volume 17 / Issue 5 / DOI: 10.2741/4021

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Article
PPAR gamma, bioactive lipids, and cancer progression
Show Less
1 Department of Medical Microbiology, Immunology and Cell Biology, Southern Illinois University School of Medicine

Academic Editor: Kounosuke Watabe

Front. Biosci. (Landmark Ed) 2012, 17(5), 1816–1834; https://doi.org/10.2741/4021
Published: 1 January 2012
(This article belongs to the Special Issue Pathogenesis of tumor progression in breast and prostate cancer)
Abstract

In this article we review the evolution of cancer research involving PPARgamma, including mechanisms, target genes, and clinical applications. For the last thirteen years, the effects of PPARgamma activity on tumor biology have been studied intensely. Most of this research has focused upon the potential for employing agonists of this nuclear receptor in cancer treatment. As a monotherapy such agonists have shown little success in clinical trials, while they have shown promise as components of combination treatments both in culture and in animal models. Other investigations have explored a possible role for PPARgamma as a tumor suppressor, and as an inducer of differentiation of cancer stem cells. Whereas early studies have yielded variable conclusions regarding the prevalence of PPARgamma mutations in cancer, the protein level of this receptor has been more recently identified as a significant prognostic marker. We predict that indicators of PPARgamma activity may also serve as predictive markers for tailoring treatments.

Share
Back to top